Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,571 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preoperative Neurological Changes on Outcomes in Large-Vessel Occlusion Due to Intracranial Atherosclerotic Disease.
Yoshimoto T, Tanaka K, Koge J, Uchida K, Imamura H, Toyoda K, Yamagami H, Sakai N, Shirakawa M, Beppu M, Matsumaru Y, Matsumoto Y, Todo K, Hayakawa M, Shindo S, Morimoto M, Takeuchi M, Ikeda H, Ishihara H, Kakita H, Sano T, Araki H, Nomura T, Sakakibara F, Yoshimura S. Yoshimoto T, et al. Among authors: ishihara h. Neurosurg Pract. 2025 Aug 22;6(3):e000156. doi: 10.1227/neuprac.0000000000000156. eCollection 2025 Sep. Neurosurg Pract. 2025. PMID: 41163650 Free PMC article.
Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis: A Randomized Clinical Trial.
Okazaki S, Tanaka K, Yazawa Y, Doijiri R, Koga M, Ihara M, Yamamoto S, Kamiyama K, Honda Y, Uchida K, Yoshimoto T, Asakura K, Omae K, Tanaka K, Maeda H, Yamamoto H, Hirano T, Toyoda K, Iguchi Y, Noguchi T, Okada Y, Kitagawa K, Sakai N, Yamagami H; ATIS-NVAF Trial Investigators. Okazaki S, et al. JAMA Neurol. 2025 Oct 6:e253662. doi: 10.1001/jamaneurol.2025.3662. Online ahead of print. JAMA Neurol. 2025. PMID: 41051787
Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma.
Ishihara H, Nishimura K, Nemoto Y, Mizoguchi S, Nakayama T, Fukuda H, Shimmura H, Hashimoto Y, Yoshida K, Iizuka J, Kondo T, Takagi T. Ishihara H, et al. Jpn J Clin Oncol. 2025 Sep 30:hyaf152. doi: 10.1093/jjco/hyaf152. Online ahead of print. Jpn J Clin Oncol. 2025. PMID: 41025729
Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis.
Nishimura K, Ishihara H, Nemoto Y, Mizoguchi S, Nakayama T, Fukuda H, Yoshida K, Shimmura H, Hashimoto Y, Iizuka J, Kondo T, Takagi T. Nishimura K, et al. Among authors: ishihara h. Int Urol Nephrol. 2025 Sep 1. doi: 10.1007/s11255-025-04771-0. Online ahead of print. Int Urol Nephrol. 2025. PMID: 40889073
1,571 results